Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.Donate to our crowdfunder
The Commission on Human Medicines (CHM) is the Government’s scientific advisory committee, from which the Medicines and Healthcare products Regulatory Agency (MHRA) seeks independent scientific advice.
The CHM considered a thorough review of the safety of human papillomavirus (HPV) vaccine at its meeting on 16 July 2015. Prior to 2015, the CHM considered reviews of HPV vaccine at meetings in September 2012, September 2010, September 2009, June 2009 and February 2009. These reviews included evaluation of United Kingdom Yellow Card reports, analysis of data from the Clinical Practice Research Datalink (CPRD), published safety studies and safety data from other countries.
Most recently, the CHM considered the safety of HPV vaccine at its meeting on 15 October 2015. At this meeting, the MHRA sought advice from the CHM on the (Co)-Rapporteurs’ assessment reports prepared for the European Medicines Agency (EMA) review into reports of postural orthostatic tachycardia syndrome and complex regional pain syndrome following HPV vaccine, in order to inform the UK position in the review.
As with all vaccines and medicines, the safety of HPV vaccine remains under continual review by the MHRA.